5F79

Influenza PB2 bound to an azaindole inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.203 
  • R-Value Work: 0.168 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza.

Bandarage, U.K.Clark, M.P.Perola, E.Gao, H.Jacobs, M.D.Tsai, A.Gillespie, J.Kennedy, J.M.Maltais, F.Ledeboer, M.W.Davies, I.Gu, W.Byrn, R.A.Nti Addae, K.Bennett, H.Leeman, J.R.Jones, S.M.O'Brien, C.Memmott, C.Bennani, Y.Charifson, P.S.

(2017) ACS Med Chem Lett 8: 261-265

  • DOI: 10.1021/acsmedchemlett.6b00487
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • JNJ-63623872 (2) is a first-in-class, orally bioavailable compound that offers significant potential for the treatment of pandemic and seasonal influenza. Early lead optimization efforts in our 7-azaindole series focused on 1,3-diaminocyclohexyl amid ...

    JNJ-63623872 (2) is a first-in-class, orally bioavailable compound that offers significant potential for the treatment of pandemic and seasonal influenza. Early lead optimization efforts in our 7-azaindole series focused on 1,3-diaminocyclohexyl amide and urea substitutions on the pyrimidine-7-azaindole motif. In this work, we explored two strategies to eliminate observed aldehyde oxidase (AO)-mediated metabolism at the 2-position of these 7-azaindole analogues. Substitution at the 2-position of the azaindole ring generated somewhat less potent analogues, but reduced AO-mediated metabolism. Incorporation of a ring nitrogen generated 7-azaindazole analogues that were equipotent to the parent 2-H-7-azaindole, but surprisingly, did not appear to improve AO-mediated metabolism. Overall, we identified multiple 2-substituted 7-azaindole analogues with enhanced AO stability and we present data for one such compound (12) that demonstrate a favorable oral pharmacokinetic profile in rodents. These analogues have the potential to be further developed as anti-influenza agents for the treatment of influenza.


    Organizational Affiliation

    Vertex Pharmaceuticals Incorporated , 50 Northern Avenue, Boston, Massachusetts 02210, United States.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Polymerase basic protein 2
A
169Influenza A virus (strain A/Beijing/39/1975 H3N2)Mutation(s): 0 
Gene Names: PB2
Find proteins for Q30NP1 (Influenza A virus (strain A/Beijing/39/1975 H3N2))
Go to UniProtKB:  Q30NP1
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
4V7
Query on 4V7

Download SDF File 
Download CCD File 
A
N-[(1R,3S)-3-({5-fluoro-2-[5-fluoro-2-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]pyrimidin-4-yl}amino)cyclohexyl]pyrrolidine-1-carboxamide
C23 H27 F2 N7 O2
GNSZLKHAOIWBEM-LSDHHAIUSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.4 Å
  • R-Value Free: 0.203 
  • R-Value Work: 0.168 
  • Space Group: P 65
Unit Cell:
Length (Å)Angle (°)
a = 80.970α = 90.00
b = 80.970β = 90.00
c = 54.620γ = 120.00
Software Package:
Software NamePurpose
BUSTER-TNTrefinement
Aimlessdata scaling
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2015-12-07 
  • Released Date: 2016-12-07 
  • Deposition Author(s): Jacobs, M.D.

Revision History 

  • Version 1.0: 2016-12-07
    Type: Initial release
  • Version 1.1: 2017-03-01
    Type: Database references